Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksaç, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, María‐Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tobias Kampfenkel, Weiping Liu, Jianping Wang, Michele Kosh, NamPhuong Tran, Robin Carson, Pieter Sonneveld